RG
OVID icon

Redmile Group’s Ovid Therapeutics OVID Stock Holding History

Redmile Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-40,674
Closed -$137K – 75
2021
Q3 		$137K Hold
40,674
– – ﹤0.01% 75
2021
Q2 		$159K Sell
40,674
-81,276
-67% -$321K ﹤0.01% 86
2021
Q1 		$490K Hold
121,950
– – 0.01% 83
2020
Q4 		$282K Hold
121,950
– – ﹤0.01% 86
2020
Q3 		$700K Hold
121,950
– – 0.01% 79
2020
Q2 		$899K Hold
121,950
– – 0.02% 78
2020
Q1 		$363K Hold
121,950
– – 0.01% 67
2019
Q4 		$506K Hold
121,950
– – 0.01% 62
2019
Q3 		$395K Sell
121,950
-615,600
-83% -$1.4M 0.01% 61
2019
Q2 		$1.36M Hold
737,550
– – 0.04% 67
2019
Q1 		$1.3M Hold
737,550
– – 0.04% 68
2018
Q4 		$1.78M Buy
737,550
+7,400
+1% +$33.8K 0.07% 62
2018
Q3 		$4.14M Buy
730,150
+608,200
+499% +$4.61M 0.13% 64
2018
Q2 		$951K Sell
121,950
-38,768
-24% -$333K 0.03% 68
2018
Q1 		$1.14M Sell
160,718
-152,064
-49% -$1.23M 0.04% 58
2017
Q4 		$3.09M Sell
312,782
-138,400
-31% -$1.27M 0.13% 59
2017
Q3 		$3.77M Buy
451,182
+2,401
+0.5% +$20K 0.19% 54
2017
Q2 		$4.24M Buy
+448,781
New +$5.86M 0.26% 53

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Redmile Group's OVID Position: Q4 2021 in Review

Redmile Group sold out of Ovid Therapeutics (OVID) in Q4 2021, closing a stake of 40,674 shares — an estimated $137K sold.

Redmile Group first reported a position in OVID in Q2 2017 and held it in 18 quarters. The position peaked at $4.24M in Q2 2017. 67 funds tracked by Wall St. Rank hold OVID as of Q4 2021.

  • Redmile Group reported no remaining Ovid Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Redmile Group sold 40,674 Ovid Therapeutics shares in Q4 2021, an estimated $137K.
  • Redmile Group first reported a position in Ovid Therapeutics in Q2 2017 and held it in 18 quarters.
  • Redmile Group's Ovid Therapeutics position peaked at $4.24M in Q2 2017.
  • 67 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2021.

Based on Redmile Group's 13F filing for Q4 2021, filed 14 Feb 2022.